BURLINGAME, Calif. & CALGARY, Alberta--(BUSINESS WIRE)--Parvus Therapeutics, a biopharmaceutical company focused on the development of disease-specific immunoregulatory medicines to treat autoimmune ...
Parvus announces two new rugged embedded DC/DC power supply boards with built-in MIL-STD power conditioning and EMI filtering for military ground vehicles and aircraft installations Operating Temp: ...
CALGARY, Alberta--(BUSINESS WIRE)--Parvus Therapeutics, a biopharmaceutical company developing disease-modifying nanomedicines to halt or reverse autoimmune disease without causing general immune ...
SALT LAKE CITY, UT--(Marketwire - Mar 18, 2013) - Eurotech subsidiary Parvus Corporation announces that the DuraCOR 830, a rugged tactical mission processor subsystem based on an ultra-low power Intel ...
Genentech, a member of the Roche Group, today launched an up-to-$800 million partnership with Parvus Therapeutics to develop, manufacture, and commercialize new treatments for inflammatory bowel ...
Novartis, which has had a busy week for its CAR-T and NASH programs, today moved onto diabetes after penning a new pact with virtual Canadian biotech Parvus Therapeutics to use its leading tech. Exact ...
Canada’s Parvus Therapeutics has signed a deal with Roche’s Genentech unit to develop, manufacture and market drugs for inflammatory bowel disease, autoimmune liver diseases, and coeliac disease. The ...
MILAN, June 24 (Reuters) - Parvus Asset Management Europe, a major UBI shareholder, will decide whether to accept Intesa Sanpaolo's takeover offer for the Italian bank after publication of the ...
* Parvus therapeutics says has entered into a license and collaboration agreement with novartis for its lead navacim for treating type 1 diabetes * Parvus-Under terms,novartis receives exclusive, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results